37 results about "Mycoplasma hyopneumoniae Antigen" patented technology

The invention provides a fusion protein and a composition and application of the mycoplasma pneumonia vaccine containing the fusion protein. The fusion protein includes Pseudomonas aeruginosa exotoxin A domain I and II, Mycoplasma hyopneumoniae antigenic protein and carboxyl terminal part, and the Mycoplasma hyopneumoniae antigenic protein includes NrdF protein, P102 protein, P97R1 protein, P97R2 protein, P97R1 protein Any protein in -NrdF protein, P97R2-NrdF protein. The invention also discloses a vaccine composition containing immune amount fusion protein and its application in the preparation of medicine for preventing and / or treating swine mycoplasma pneumonia. The vaccine composition can carry out a large amount of recombinant expression on the components of the vaccine composition by means of genetic engineering, which not only takes a short time, but also facilitates large-scale production; the vaccine composition can produce both humoral immunity and cellular immunity , can obtain a better immune effect.

The present invention provides a vaccine composition comprising an immune amount of Mycoplasma hyopneumoniae antigen, an immune amount of a Haemophilus parasuis antigen, and an immune amount of an antigen of Porcine Reproductive and Respiratory Syndrome Virus. The vaccine composition is infected with porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae and Haemophilus parasuis on the 14th day after the second immunization, and can protect more than 80% of pigs without mutual interference between antigens, and achieves impressive results. Satisfactory immune effect.

The present invention provides a vaccine adjuvant composition for treatment or prevention of swine infectious diseases. The vaccine adjuvant composition contains a milkvetch root extract, a polymer and an antigen component, or contains a milkvetch root extract, a polymer, cyclodextrin and an antigen component. The vaccine adjuvant can be combined with porcine circovirus antigen or mycoplasma hyopneumoniae antigen so as to substantially improve vaccine immune efficacy, wherein the original immune efficacy can be achieved after reducing the amount of the vaccine to the half of the amount of the original antigen; and test results of the vaccine adjuvant with a plurality of doses show that: the vaccine adjuvant does not have a significant side effect, and provides significantly reduced side effect compared with the commonly used oil phase adjuvant.